Combining experience with innovation across the early drug discovery process
Our fully integrated scientific team translates expertise in cellular and molecular biology, medicinal, computational and analytical chemistry into the discovery and development of innovative therapies.
We have a broad portfolio of drug discovery projects based on in-house research that are unlocking the potential of novel therapeutic targets, including orphan nuclear receptors.
Internal innovation at Tes Pharma is strengthened by our collaboration with preclinical and clinical experts that ensures that our research projects are pursued with a broad and in-depth understanding of the chemistry and biology necessary to develop first-in-class new chemical entities from discovery to positive clinical data and regulatory filing.
Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.
Biomed Pharmacother. 2022 Sep;153:113380. doi: 10.1016/j.biopha.2022.113380.
Development of 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-sulfate sodium salt (INT-767): Process optimization, synthesis and characterization of metabolites.
Eur J Med Chem. 2022 Aug 20;242:114652. doi: 10.1016/j.ejmech.2022.114652.
Identification of RAD51-BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry
ACS Med Chem Lett. 2022 Jul 28;13(8):1262-1269. doi: 10.1021/acsmedchemlett.2c00063.
Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication
Immunity. 2022 Jun 14;55(6):1032-1050.e14. doi: 10.1016/j.immuni.2022.05.013.
Structural Basis of Human Dimeric α-Amino-β-Carboxymuconate-ε-Semialdehyde Decarboxylase Inhibition With TES-1025.
Front Mol Biosci. 2022 Apr 7;9:834700. doi: 10.3389/fmolb.2022.834700.
Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies.
J Med Chem. 2022 Mar 10;65(5):3962-3977. doi: 10.1021/acs.jmedchem.1c01784.
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.
J Med Chem. 2021 Dec 9;64(23):17031-17050. doi: 10.1021/acs.jmedchem.1c00605.
Ablation of liver Fxr results in an increased colonic mucus barrier in mice.
JHEP Rep. 2021 Aug 4;3(5):100344. doi: 10.1016/j.jhepr.2021.100344.
Synthesis and biological activity of cyclopropyl Δ7-dafachronic acids as DAF-12 receptor ligands.
Org Biomol Chem. 2021 Jun 28;19(24):5403-5412. doi: 10.1039/d1ob00912e.
Central anorexigenic actions of bile acids are mediated by TGR5.
Nat Metab. 2021 May;3(5):595-603. doi: 10.1038/s42255-021-00398-4.
Innovations and emerging therapies to combat renal cell damage: NAD+ as a drug target.
Antioxid Redox Signal. 2021 Dec 10;35(17):1449-1466. doi: 10.1089/ars.2020.8066.
Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration.
Gastroenterology. 2020 Sep;159(3):956-968.e8.
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
ACS Med Chem Lett. 2020 Feb 3;11(5):862-868.
Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor.
J Med Chem. 2020 Apr 9;63(7):3701-3712.
Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool.
Medchemcomm. 2019 Jun 24;10(8):1412-1419.
Exploiting Chemical Toolboxes for the Expedited Generation of Tetracyclic Quinolines as a Novel Class of PXR Agonists.
ACS Med Chem Lett. 2018 Dec 27;10(4):677-681.
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Eur J Med Chem. 2019 Mar 1;165:80-92.
De novo NAD+ synthesis enhances mitochondrial function and improves health.
Nature. 2018 Nov;563(7731):354-359.
α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis.
J Med Chem. 2018 Feb 8;61(3):745-759.
Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
Eur J Med Chem. 2018 Jan 20;144:349-358.
Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Eur J Med Chem. 2017 Dec 15;142:506-522
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
ACS Chem Biol. 2017 Oct 20;12(10):2491-2497.
Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human DeacetylaseSirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity.
J Med Chem. 2017 Mar 23;60(6):2344-2360.
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
J Med Chem. 2016 Oct 4.
Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
ChemMedChem. 2016 Jun 20;11(12):1219-26.
The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.
Sci Rep. 2015 Sep 15;5:14086.
Scaffold hopping approach on the route to selective tankyrase inhibitors.
Eur J Med Chem. 2014 Nov 24;87:611-23
Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.
Biochim Biophys Acta. 2014 Oct;1844(10):1765-72.
Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3β-hydroxy-Δ(5)-C27-steroid oxidoreductase deficiency.
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:348-60. doi: 10.1016/j.jsbmb.2014.06.008.
Probing the Binding Site of Bile Acids in TGR5.
ACS Med Chem Lett. 2013 Oct 15;4(12):1158-62. doi: 10.1021/ml400247k.
Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
J Pharmacol Exp Ther. 2014 Jul;350(1):56-68. doi: 10.1124/jpet.114.214650.
CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands.
J Biomol Screen. 2014 Jul;19(6):859-69. doi: 10.1177/1087057114526283.